Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. EZH2 inhibitor like Tazemetostat or SHR 2554 has been demonstrated its anti-tumor activity in PTCL either alone or in combination with other targeted agents. This study aims to explore the efficacy and safety of Tazemetostat in combination with Linperlisib/Golidocitinib in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma in the patients with peripheral T-cell lymphoma according to next-generation sequesing results.

NCT Number	NCT07209163
Lead Sponsor	Ruijin Hospital
Conditions	Peripheral T Cell Lymphoma
Enrollment	48 participants
Start Date	2025-10
Primary Completion	2026-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2025-10-06